- call +1-201-465-4211
- email sales@mrinsights.biz
Dementia is a collective term for disorders characterized by progressive degeneration of the brain. It impairs memory and affects behavioral, emotional, and cognitive abilities. The neuronal death or neuronal malfunction associated with the disorder manifests as shifts in mood and personality changes, difficulty in performing activities, loss of memory, and aphasia.
Scope of the Report:
This report studies the Dementia and Movement Disorder Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Dementia and Movement Disorder Treatment market by product type and applications/end industries.
The treatment for dementia is conducted through therapeutic approaches that provide symptomatic relief as the drugs intended for the treatment only treat the symptoms. The existing drugs in the market are unable to attack the underlying cause of the disease and prolong the treatment cost and time duration. This will in turn increase the demand for DMD since it will safely modify the progression of a disease.
The market is highly competitive and fragmented due to the presence of several large players that have launched successful drugs. The expiry of the patents significantly affects the performance of the manufacturers. Geographical presence, stable supply chain logistics, patent expiry, and new approvals of already established/expired drugs for additional indications are some of the major factors the manufacturers usually compete on.
The Americas is home to a large patient pool and a witnessing a rise in the geriatric population. Factors such as the focus on the government of USA towards taking initiatives to develop drugs for dementia and movement disorder (DAMD) that expands the access to effective treatment regimen for DAMD will fuel the market’s growth prospects in this region.
The global Dementia and Movement Disorder Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Dementia and Movement Disorder Treatment.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Allergan
Eisai
Novartis
Teva Pharmaceutical Industries
Amgen
Pfizer
UCB
H. Lundbeck
F. Hoffmann-La Roche
Eli Lilly
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
MAO inhibitors (monoamine oxidase)
AChE inhibitors (acetylcholinesterase)
Glutamate inhibitors
Market Segment by Applications, can be divided into
Branded drugs
Generic drugs
Off-label drugs
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Dementia and Movement Disorder Treatment Market Overview
1.1 Product Overview and Scope of Dementia and Movement Disorder Treatment
1.2 Classification of Dementia and Movement Disorder Treatment by Types
1.2.1 Global Dementia and Movement Disorder Treatment Revenue Comparison by Types (2017-2023)
1.2.2 Global Dementia and Movement Disorder Treatment Revenue Market Share by Types in 2017
1.2.3 MAO inhibitors (monoamine oxidase)
1.2.4 AChE inhibitors (acetylcholinesterase)
1.2.5 Glutamate inhibitors
1.3 Global Dementia and Movement Disorder Treatment Market by Application
1.3.1 Global Dementia and Movement Disorder Treatment Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Branded drugs
1.3.3 Generic drugs
1.3.4 Off-label drugs
1.4 Global Dementia and Movement Disorder Treatment Market by Regions
1.4.1 Global Dementia and Movement Disorder Treatment Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Dementia and Movement Disorder Treatment Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Dementia and Movement Disorder Treatment Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Dementia and Movement Disorder Treatment Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Dementia and Movement Disorder Treatment Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Dementia and Movement Disorder Treatment Status and Prospect (2013-2023)
1.5 Global Market Size of Dementia and Movement Disorder Treatment (2013-2023)
2 Manufacturers Profiles
2.1 Allergan
2.1.1 Business Overview
2.1.2 Dementia and Movement Disorder Treatment Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Allergan Dementia and Movement Disorder Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.2 Eisai
2.2.1 Business Overview
2.2.2 Dementia and Movement Disorder Treatment Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Eisai Dementia and Movement Disorder Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.3 Novartis
2.3.1 Business Overview
2.3.2 Dementia and Movement Disorder Treatment Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Novartis Dementia and Movement Disorder Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.4 Teva Pharmaceutical Industries
2.4.1 Business Overview
2.4.2 Dementia and Movement Disorder Treatment Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Teva Pharmaceutical Industries Dementia and Movement Disorder Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.5 Amgen
2.5.1 Business Overview
2.5.2 Dementia and Movement Disorder Treatment Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Amgen Dementia and Movement Disorder Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.6 Pfizer
2.6.1 Business Overview
2.6.2 Dementia and Movement Disorder Treatment Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Pfizer Dementia and Movement Disorder Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.7 UCB
2.7.1 Business Overview
2.7.2 Dementia and Movement Disorder Treatment Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 UCB Dementia and Movement Disorder Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.8 H. Lundbeck
2.8.1 Business Overview
2.8.2 Dementia and Movement Disorder Treatment Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 H. Lundbeck Dementia and Movement Disorder Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.9 F. Hoffmann-La Roche
2.9.1 Business Overview
2.9.2 Dementia and Movement Disorder Treatment Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 F. Hoffmann-La Roche Dementia and Movement Disorder Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.10 Eli Lilly
2.10.1 Business Overview
2.10.2 Dementia and Movement Disorder Treatment Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Eli Lilly Dementia and Movement Disorder Treatment Revenue, Gross Margin and Market Share (2016-2017)
3 Global Dementia and Movement Disorder Treatment Market Competition, by Players
3.1 Global Dementia and Movement Disorder Treatment Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Dementia and Movement Disorder Treatment Players Market Share
3.2.2 Top 10 Dementia and Movement Disorder Treatment Players Market Share
3.3 Market Competition Trend
4 Global Dementia and Movement Disorder Treatment Market Size by Regions
4.1 Global Dementia and Movement Disorder Treatment Revenue and Market Share by Regions
4.2 North America Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
4.3 Europe Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
4.5 South America Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
5 North America Dementia and Movement Disorder Treatment Revenue by Countries
5.1 North America Dementia and Movement Disorder Treatment Revenue by Countries (2013-2018)
5.2 USA Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
5.3 Canada Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
5.4 Mexico Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
6 Europe Dementia and Movement Disorder Treatment Revenue by Countries
6.1 Europe Dementia and Movement Disorder Treatment Revenue by Countries (2013-2018)
6.2 Germany Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
6.3 UK Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
6.4 France Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
6.5 Russia Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
6.6 Italy Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Dementia and Movement Disorder Treatment Revenue by Countries
7.1 Asia-Pacific Dementia and Movement Disorder Treatment Revenue by Countries (2013-2018)
7.2 China Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
7.3 Japan Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
7.4 Korea Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
7.5 India Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
8 South America Dementia and Movement Disorder Treatment Revenue by Countries
8.1 South America Dementia and Movement Disorder Treatment Revenue by Countries (2013-2018)
8.2 Brazil Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
8.3 Argentina Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
8.4 Colombia Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Dementia and Movement Disorder Treatment by Countries
9.1 Middle East and Africa Dementia and Movement Disorder Treatment Revenue by Countries (2013-2018)
9.2 Saudi Arabia Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
9.3 UAE Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
9.4 Egypt Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
9.5 Nigeria Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
9.6 South Africa Dementia and Movement Disorder Treatment Revenue and Growth Rate (2013-2018)
10 Global Dementia and Movement Disorder Treatment Market Segment by Type
10.1 Global Dementia and Movement Disorder Treatment Revenue and Market Share by Type (2013-2018)
10.2 Global Dementia and Movement Disorder Treatment Market Forecast by Type (2018-2023)
10.3 MAO inhibitors (monoamine oxidase) Revenue Growth Rate (2013-2023)
10.4 AChE inhibitors (acetylcholinesterase) Revenue Growth Rate (2013-2023)
10.5 Glutamate inhibitors Revenue Growth Rate (2013-2023)
11 Global Dementia and Movement Disorder Treatment Market Segment by Application
11.1 Global Dementia and Movement Disorder Treatment Revenue Market Share by Application (2013-2018)
11.2 Dementia and Movement Disorder Treatment Market Forecast by Application (2018-2023)
11.3 Branded drugs Revenue Growth (2013-2018)
11.4 Generic drugs Revenue Growth (2013-2018)
11.5 Off-label drugs Revenue Growth (2013-2018)
12 Global Dementia and Movement Disorder Treatment Market Size Forecast (2018-2023)
12.1 Global Dementia and Movement Disorder Treatment Market Size Forecast (2018-2023)
12.2 Global Dementia and Movement Disorder Treatment Market Forecast by Regions (2018-2023)
12.3 North America Dementia and Movement Disorder Treatment Revenue Market Forecast (2018-2023)
12.4 Europe Dementia and Movement Disorder Treatment Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Dementia and Movement Disorder Treatment Revenue Market Forecast (2018-2023)
12.6 South America Dementia and Movement Disorder Treatment Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Dementia and Movement Disorder Treatment Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Dementia and Movement Disorder Treatment Picture
Table Product Specifications of Dementia and Movement Disorder Treatment
Table Global Dementia and Movement Disorder
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
